Dr Pradeep Thapa american Oncology Hospitals

• MBBS from TN Medical College, Mumbai Central, Mumbai -2007
• DRM from Institute of Nuclear Medicine and Allied Sciences, Delhi University - 2010- 2012
• DNB Nuclear medicine, Radiation Medicine Centre, Mumbai - 2013-2015
• Fellow European Board of Nuclear Medicine (FEBNM) - October 2018

Dr Thapa has worked extensively on PET CT, SPECT-CT & Gamma Camera system, with experience in managing patients with thyroid disorders including radio-iodine therapy treatment. Reading and interpretation of PET CT, Gamma camera, SPECT CT scan, including new PET tracers Ga-68 DOTANOC and Ga-68 PSMA.

Also has an experience in administrating radionuclides for Nuclear Medicine Therapy using Lutetium DOTANOC for Neuroendocrine tumours, I-131 for Carcinoma Thyroid, Sm-153 EDTMP and Lu-177 EDTMP for bone pain palliation and Iodine 131 MIBG for Metastatic Inoperable Neuroblastomas, Paraganglioma, Carcinoid Tumours and Pheochromocytomas & Lutetium 177 PSMA for Metastatic Prostate Cancer.

• Consultant (Nuclear Medicine) - Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, Telangana - December, 2022 to May,2024
• Consultant (Nuclear Medicine), Venkateshwar Hospital, Dwarka, New Delhi - June 2016 – December 2022
• Consultant in (Nuclear Medicine), Vijaya Diagnostic Centre, Hyderabad, Telangana - August 2015 – June 2016
• Fellowship in PET-CT in Nuclear Medicine - Department, Medanta Hospital, Gurgaon, Haryana - July 2015 – August 2015
• Senior Resident in the Department of Nuclear Medicine, Safdarjung Hospital, New Delhi - June 2012 – February 2013

• Thapa P, Basu S. Leveraging the power of non-radium radionuclide treatments in bone metastases. Q J Nucl Med Mol Imaging. 2019 Jul 1.
• Basu S, Chakraborty S, Parghane RV, Kamaldeep, Ranade R, Thapa P. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [ 177 Lu] Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting. Am J Nucl Med Mol Imaging. 2020 Aug 25;10(4):178-211.
• Thapa P, Kalshetty A, Basu S. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary: A subgroup-specific analysis based on clinical presentation. World J Nucl Med. 17(4):219-222. Oct-Dec 2017.
• Dutta D, Pandey RK, Gogoi R, Solanki N, Madan R, Mondal A, Dogra S, Thapa P. Occult phosphaturic mesenchymal tumour of femur cortex causing oncogenic osteomalacia - diagnostic challenges and clinical outcomes. Endokrynol Pol. 69(2):205-210. 2018.
• Thapa P, Parghane R, Basu S. 177-Lu DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites. World J Nucl Med. 16(3):223-228. Jul-Sep 2017.

• Recipient of Alavi-Mandell Award for publication titled “Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases”.
• Best poster recipient for “Comparative study between Tc-99m Methionine and C-11 Methionine in detection of recurrence in primary brain tumor” at Annual Conference of Society of Nuclear Medicine, India, 2011.

DMC 42191

• Member of European Association of Nuclear Medicine.
• Member of Society of Nuclear Medicine, India.

• English
• Hindi